checkAd
    Arrowhead Pharmaceuticals Aktie
    23,130
     
    USD
    +4,57 %
    +1,010 USD
    Letzter Kurs 02:00:00 Nasdaq
    23,120
     
    USD
    100 STK
    Geldkurs 29.04.24
    23,150
     
    USD
    2.200 STK
    Briefkurs 29.04.24
    ISIN: US04280A1007 · WKN: A2AGYB · SYM: ARWR · USA

    Neueste Nachrichten

    Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
    29.04.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
    26.04.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
    24.04.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
    24.04.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
    07.04.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    01.04.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
    25.03.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
    08.03.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
    04.03.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
    06.02.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
    22.01.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
    05.01.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals